Tirzepatide
aka Tirzepatide (GIP/GLP-1 dual receptor agonist — Mounjaro, Zepbound)
Mechanism
Tirzepatide is a unimolecular dual GIP and GLP-1 receptor agonist with a half-life of approximately 5 days, enabling once-weekly subcutaneous dosing. It is FDA-approved as Mounjaro for type 2 diabetes (2022), Zepbound for chronic weight management in adults with obesity or overweight with a weight-related comorbidity (2023), and Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity (2024). It carries a BOXED WARNING for thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Identification
| CAS number | 2023788-19-2 |
|---|---|
| Molecular formula | C225H348N48O68 |
| Sequence | YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPSamide |
| Typical dose | 2.5–15 mg once weekly subcutaneous injection (research studies mirror clinical titration: start 2.5 mg/week, escalate by 2.5 mg every 4 weeks to max 15 mg/week) |
| Half-life | ~5 days (~120 hours) |
Vendors selling Tirzepatide
| Vendor | Size | Price | Listed purity | Trust |
|---|---|---|---|---|
| Peptide Partners | 80 mg | $297.00 | — | 99 |
| Crush Research | 20 mg | — | — | 95 |
| Crush Research | 30 mg | $199.00 | — | 95 |
| Orbitrex Peptides | 10 mg | $59.99 | — | 95 |
| Orbitrex Peptides | 15 mg | $79.99 | — | 95 |
| Orbitrex Peptides | 30 mg | $129.99 | — | 95 |
| Orbitrex Peptides | 60 mg | $199.99 | — | 95 |
| Profound Aminos | 5 mg | $69.00 | — | 95 |
| Skye Peptides | 10 mg | $89.00 | — | 90 |
| Qihang Peptide | — | — | — | 87 |
| Peptidegurus | 6 mg | — | — | 84 |
| Peptidegurus | 10 mg | — | — | 84 |
| Peptidegurus | 12 mg | — | — | 84 |
| Peptidegurus | 15 mg | — | — | 84 |
| Peptidegurus | 16 mg | — | — | 84 |
| Peptidegurus | 30 mg | — | — | 84 |
| Peptidegurus | 50 mg | — | — | 84 |
| Reta Peptide | — | $265.00 | — | 83 |
| Cocer Peptides | 10 mg | $110.00 | — | 82 |
| Blank Peptides | 30 mg | $120.00 | — | 81 |
| Blank Peptides | 10 mg | $120.00 | — | 81 |
| Crystal Peptides | 10 mg | $99.00 | — | 66 |
| Crystal Peptides | 20 mg | $159.99 | — | 66 |
| Crystal Peptides | 30 mg | $199.99 | — | 66 |
| Peptiatlas | — | — | — | 51 |
| Peptiatlas | — | — | — | 51 |
| Zjpeptix | 30 mg | — | — | 50 |
| Hkuppeptide | 20 mg | $10.00 | — | 50 |
| MEI-PEPETIDE | — | — | — | 48 |
| DongCheng Peptide | — | — | — | 46 |
| Mandy | 5 mg | $26.00 | — | 43 |
| HongDa Peptide | — | $43.00 | — | 43 |
| zztai Peptide Ltd | 5 mg | $48.00 | — | 43 |
| zztai Peptide Ltd | 10 mg | $68.00 | — | 43 |
| zztai Peptide Ltd | 15 mg | $87.00 | — | 43 |
| zztai Peptide Ltd | 20 mg | $110.00 | — | 43 |
| zztai Peptide Ltd | 30 mg | $155.00 | — | 43 |
| zztai Peptide Ltd | 40 mg | $200.00 | — | 43 |
| zztai Peptide Ltd | 50 mg | $245.00 | — | 43 |
| zztai Peptide Ltd | 60 mg | $280.00 | — | 43 |
| MJT peptides | 5 mg | $40.00 | — | 39 |
| HK Peptide Ltd (hk peptides) | 30 mg | $150.00 | — | 37 |
| HK Peptide Ltd (hk peptides) | 60 mg | $300.00 | — | 37 |
| NG Peptide | 20 mg | $65.00 | — | — |
| Strate Labs | 10 mg | $39.95 | — | — |
| Strate Labs | 30 mg | $69.95 | — | — |
| Strate Labs | 60 mg | $149.95 | — | — |
| Bulk Peptides | 20 mg | $380.00 | — | — |
| Polaris Peptides | 60 mg | $309.00 | — | — |
| Polaris Peptides | 50 mg | $270.00 | — | — |
| Polaris Peptides | 30 mg | $225.00 | — | — |
| Polaris Peptides | 10 mg | $89.00 | — | — |
| Polaris Peptides | 5 mg | $55.00 | — | — |
Research
Objective Obesity is associated with chronic low-grade inflammation, increased cardiovascular risk, and alterations in platelet indices [1-5]. Mean platelet volume (MPV) is an easily obtainable surrogate marker that has been linked to platelet activation and inflammatory burden [4, 6-8].
source →Hypersensitivity reactions to glucagon-like peptide-1 receptor agonists (GLP-1RAs) are uncommon but clinically significant given their expanding use for obesity and type 2 diabetes.
source →Background To evaluate the association between tirzepatide use and 1-year risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease, compared with GLP-1 (glucagon-like peptide-1) receptor agonists.
source →Background Obesity is a major risk factor for chronic kidney disease (CKD), contributing to kidney dysfunction through metabolic alterations and chronic inflammation.
source →Background Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated its efficacy in clinical trials; however, real-world evidence on treatment satisfaction and experiences among people with obesity or overweight (PwO) and their…
source →Aims To assess the effect of tirzepatide, a glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonist, on cardiovascular outcomes and mortality in subjects with overweight/obesity, or type 2 diabetes mellitus (T2DM).
source →Background The SUMMIT trial showed that the long-acting glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist tirzepatide decreased risk of cardiovascular death or worsening heart failure (HF) in patients with obesity-related heart failure with preserved ejection fraction (H…
source →Aims Tirzepatide, a first-in-class dual GIP/GLP-1 receptor agonist, was approved by the FDA for type 2 diabetes mellitus (2022) and chronic weight management (2023). Despite superior efficacy in trials, its real-world safety profile remains incompletely characterised.
source →Background Obesity is a major risk factor for the development of degenerative aortic stenosis (AS), yet no pharmacologic therapy has been proven to prevent AS onset.
source →Background Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist used in patients with type 2 diabetes and obesity.
source →This retrospective cohort study evaluated whether semaglutide and tirzepatide reduce the risk of falls and femoral fractures in older adults with type 2 diabetes and overweight or obesity. The findings showed significantly lower risks of both outcomes compared with DPP-4 inhibitors.
source →The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.
source →The GRAMS study objectives are to assess the musculoskeletal changes that occur after weight loss using GLP-1 based therapy. A lifestyle intervention with diet and exercise is included to assess any mitigating effects are provided, versus a control group with regular exercise and diet.
source →This study investigates the long-term effects of anti-obesity medications (Semaglutide and Tirzepatide) on energy metabolism (24-hour energy expenditure and substrate oxidation) and body composition via Dual-energy X-ray absorptiometry (DXA)
source →This multicenter retrospective observational study evaluates the real-world use of tirzepatide in adult patients with post-bariatric weight regain and in patients with obesity undergoing preoperative management.
source →RCT (SURMOUNT-4): continued tirzepatide maintained weight reduction; withdrawal led to substantial regain.
source →This single-center, retrospective observational cohort study evaluated early changes in non-invasive hepatic and metabolic indices (FIB-4, APRI, HSI, and the triglyceride-glucose \[TyG\] index) in adults with overweight or obesity who received once-weekly subcutaneous semaglutide or tirzepatide for metabolic risk reduc…
source →The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriatic arthritis and achieve…
source →Evaluation of biomarkers for risk of developing breast cancer in women with obesity who are using tirzepatide to achieve weight loss.
source →Phase 3 RCT (SURMOUNT-2): tirzepatide for obesity in adults with type 2 diabetes; significant weight reduction vs placebo.
source →Phase 3 RCT (SURMOUNT-1): once-weekly tirzepatide produced up to ~21% mean weight loss vs placebo over 72 weeks in adults with obesity.
source →The purpose of the trial is to assess the efficacy and safety of tirzepatide taken once a week to insulin glargine taken once daily in participants with type 2 diabetes and increased cardiovascular risk. The study will last about 108 weeks and may include up to 30 visits.
source →